In the first BACE event dedicated to Epigenetic Therapeutics we hosted Eric Campeau, PhD, Vice President of Translational Biology at Zenith Epigenetics Ltd.
Eric helped us explore the potential and the drug development trajectory of the BET inhibitors in two indications. In his talk “Translating epigenetic-based therapies from preclinical programs into clinical trials: examples with BET bromodomain inhibitors” he told us about challenges of translating between preclinical models and clinical trials, and showed us how it is important to continue learning from the results of those trials to find the right fit between the drug and the patient group.
If you would like to learn more about the work discussed in this presentation, here is some further reading:
Clinical trial results in CRPC: https://clincancerres.aacrjournals.org/content/26/20/5338.abstract
Mechanistic insights into mechanism of action (June 2021): https://clincancerres.aacrjournals.org/content/27/17/4923.abstract
Links to past presentations and poster from Zenith at: https://www.zenithepigenetics.com/Science-Epigenetics/publications-posters
Bio Bay Area 
One thought on “BACE event on Epigenetic Therapeutics – September 2021”